tbuckley/cabot-search huggingface dataset:
Monitoring adherence guidelines helps improving care for lung cancer patient.
Authors: Abdul Rahman Jazieh, Mohammed Omar Farouq Al-kaiyat, Ashwaq Aman Mohammed Alolayan, Reem Al Sudairy, Ahmed Gasmelseed
Journal: Journal of Clinical Oncology (2014)

e17595 Background: Adherence to clinical management guidelines has positive impact on cancer patient outcome. We describe the results of our evaluation of adherence to lung cancer guidelines at our institution, a tertiary medical care center at Riyadh, Saudi Arabia. Methods: A guideline auditing tool was developed, the form included variables about confirming pathological diagnosis, molecular testing, staging, discussion at tumor board and treatment selection. The form was piloted and tested by two independent clinical research coordinators then completed for all patients with lung cancer seen in 2012. Findings of 2012 were shared and discussed with Thoracic Tumor Board members to encourage the team to improve their compliance and data were gathered for 2013. Results: 73 patients were included (49 for 2012 and 24 for 2013). Presentation of new cases at tumor board improved from 35% to 58%. Testing for EGFR mutation for non-squamous cell lung cancer improved from 56% to 100%. Staging was documented in 95% of the cases both years. All patients with EGFR mutation received Tyrosine Kinase Inhibitors (TKI) except one that was identified during the audit and was started on TKI. Conclusions: Monitoring adherence to guidelines and involvement of the multidisciplinary team did help in improving compliance with certain recommendations that will have positive impact on patient care and outcome.
POTENTIAL CLINICAL APPLICATION OF LCZ696 IN REAL LIFE CLINICAL PRACTICE BASED ON 2016 ACC/AHA/HFSA AND ESC HEART FAILURE GUIDELINES CRITERIA: RESULTS FROM TREAT HF STUDY
Authors: Yuksel Cavusoglu, Hakki Kaya, Mehmet Birhan Yilmaz
Journal: Journal of the American College of Cardiology (2017)
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Authors: Akihiko Murata, Kazuhiro Yoshida, Kiyoshi Maeda, Koji Ikejiri, Yoshinori Munemoto, Kazuaki Sasaki, Chu Matsuda, Masanori Kotake, Toyokuni Suenaga, Hiroyuki Matsuda, Hideo Baba, Chikuma Hamada, Eiji Oki, Yasunori Emi, Shigetoyo Saji, Yoshihiko Maehara
Journal: Journal of Clinical Oncology (2015)

3515 Background: The ACTS-RC trial is a phase III trial designed to superiority of S-1 (tegafur, 5-chloro-2,4-dihydropyrimidine, and potassium oxonate) to UFT (uracil and tegafur), a standard treatment in Japan as adjuvant chemotherapy for curatively resected stage II/III rectal cancer. Methods: 20-80 aged patients (pts) with stage II/III rectal cancer who underwent curative surgery without preoperative therapy randomly assigned to receive UFT (500, or 600mg/day according to BSA on days 1 to 5 days, followed by 2 days rest) for 1 year or S-1 (80, 100, or 120mg/day according to BSA on days 1 to 28, followed by 14 days rest) for 1 year. The primary endpoint was Relapse-free survival (RFS). The 5-year RFS rate in the UFT group was assumed to be 70%. We calculated that a total enrollment of 800 pts was needed for a hazard ratio (HR) of 0.70 in the S-1 group as compared with the UFT group, with the use of the log-rank test, two-sided alpha of 0.05, and power of 0.80. Results: A total of 959 pts were randomly assigned between April 2006 and March 2009 (480 pts in UFT group, 479 pts in S-1 group). Median age: 63 years, upper/lower rectum: 52%/48%. The groups were balanced. At a median follow-up of 5.02 years, 5-year RFS rate was 61.7%(95%CI: 57.1-65.9%)in the UFT group and 66.4%(95%CI:61.9-70.5%) in the S-1 group. The HR of RFS was 0.773(95%CI: 0.625-0.955) and superiority of S-1 was demonstrated (p = 0.0165). The completion rate of the protocol treatment was 61.8% in UFT group and 61.3% in S-1 group. 5-year overall survival rate was 80.2%(95%CI: 76.3-83.5%)in the UFT group and 82.0%(95%CI:78.3-85.2%) in the S-1 group. The overall incidence of grade ≥ 3 adverse events in UFT group and S-1 group were 11.7% and 13.4%: anemia(1.3% v 1.3%), diarrhea(2.3% v 2.6%), anorexia(1.0% v 2.6%), nausea(0.4% v 1.3%), hyperbilirubinemia (1.0% v 1.3%), AST(1.5% v 0.9%) and ALT(2.3% v 0.9%), respectively. Conclusions: Adjuvant chemotherapy using S-1 demonstrated improved 5-year RFS in pts with curatively resected stage II/III rectal cancer. S-1 is an additional adjuvant treatment option for these pts. Clinical trial information: C000000385.
Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients
Authors: Peter L. Johansson, Bjorn Andreasson, Robyn Scherber, Amylou Dueck, Jan Samuelsson, Gunnar Birgegard, Ayalew Tefferi, Ruben A. Mesa
Journal: Blood (2010)
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial
Authors: Theo Ruers, Frits Van Coevorden, Cornelis J. A. Punt, Jean-Pierre E. N. Pierie, Inne Borel-Rinkes, Jonathan A. Ledermann, Graeme Poston, Wolf Bechstein, Marie-Ange Lentz, Murielle Mauer, Gunnar Folprecht, Eric Van Cutsem, Michel Ducreux, Bernard Nordlinger
Journal: JNCI Journal of the National Cancer Institute (2017)

Tumor ablation is often employed for unresectable colorectal liver metastases. However, no survival benefit has ever been demonstrated in prospective randomized studies. Here, we investigate the long-term benefits of such an aggressive approach.In this randomized phase II trial, 119 patients with unresectable colorectal liver metastases (n < 10 and no extrahepatic disease) received systemic treatment alone or systemic treatment plus aggressive local treatment by radiofrequency ablation ± resection. Previously, we reported that the primary end point (30-month overall survival [OS] > 38%) was met. We now report on long-term OS results. All statistical tests were two-sided. The analyses were according to intention to treat.At a median follow up of 9.7 years, 92 of 119 (77.3%) patients had died: 39 of 60 (65.0%) in the combined modality arm and 53 of 59 (89.8%) in the systemic treatment arm. Almost all patients died of progressive disease (35 patients in the combined modality arm, 49 patients in the systemic treatment arm). There was a statistically significant difference in OS in favor of the combined modality arm (hazard ratio [HR] = 0.58, 95% confidence interval [CI] = 0.38 to 0.88, P = .01). Three-, five-, and eight-year OS were 56.9% (95% CI = 43.3% to 68.5%), 43.1% (95% CI = 30.3% to 55.3%), 35.9% (95% CI = 23.8% to 48.2%), respectively, in the combined modality arm and 55.2% (95% CI = 41.6% to 66.9%), 30.3% (95% CI = 19.0% to 42.4%), 8.9% (95% CI = 3.3% to 18.1%), respectively, in the systemic treatment arm. Median OS was 45.6 months (95% CI = 30.3 to 67.8 months) in the combined modality arm vs 40.5 months (95% CI = 27.5 to 47.7 months) in the systemic treatment arm.This phase II trial is the first randomized study demonstrating that aggressive local treatment can prolong OS in patients with unresectable colorectal liver metastases.
CYSTATIN C IS ASSOCIATED WITH THE RISK OF ADVERSE OUTCOMES INDEPENDENT OF ESTABLISHED AND NOVEL CARDIORENAL MARKERS: AN ANALYSIS FROM THE SOLID-TIMI 52 TRIAL
Authors: Simon Correa Gaviria, David Morrow, Eugene Braunwald, Rich Davies, Erica Goodrich, Sabina Murphy, Christopher Cannon, Michelle O'Donoghue
Journal: Journal of the American College of Cardiology (2017)
Loss of T-cell protein tyrosine phosphatase in the intestinal epithelium promotes local inflammation by increasing colonic stem cell proliferation
Authors: Stéphanie Bussières-Marmen, Valérie Vinette, Jeremy Gungabeesoon, Isabelle Aubry, Luis Alberto Pérez-Quintero, Michel L Tremblay
Journal: Cellular and Molecular Immunology (2017)

T-cell protein tyrosine phosphatase (TC-PTP) has a critical role in the development of the immune system and has been identified as a negative regulator of inflammation. Single-nucleotide polymorphisms in the TC-PTP locus have been associated with increased susceptibility to inflammatory bowel diseases (IBDs) in patients. To further understand how TC-PTP is related to IBDs, we investigated the role of TC-PTP in maintaining the intestinal epithelial barrier using an in vivo genetic approach. Intestinal epithelial cell (IEC)-specific deletion of TC-PTP was achieved in a mouse model at steady state and in the context of dextran sulphate sodium (DSS)-induced colitis. Knockout (KO) of TC-PTP in IECs did not result in an altered intestinal barrier. However, upon DSS treatment, IEC-specific TC-PTP KO mice displayed a more severe colitis phenotype with a corresponding increase in the immune response and inflammatory cytokine profile. The absence of TC-PTP caused an altered turnover of IECs, which is further explained by the role of the tyrosine phosphatase in colonic stem cell (CoSC) proliferation. Our results suggest a novel role for TC-PTP in regulating the homeostasis of CoSC proliferation. This supports the protective function of TC-PTP against IBDs, independently of its previously demonstrated role in intestinal immunity.
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Authors: Markus Frederic Renschler, Isamu Okamoto, Jeremy K. Hon, Vera Hirsh, Shaker R. Dakhil, Ray D. Page, James Orsini, Hui Zhang, Mark A. Socinski
Journal: Journal of Clinical Oncology (2012)

7592 Background: Treatment of advanced NSCLC differs by histology, with fewer options and poorer outcomes in pts with squamous histology. In a phase III trial of nab-paclitaxel (nab-P, 130 nm albumin-bound paclitaxel particles) + carboplatin (C) vs solvent-based paclitaxel (sb-P) + C, the primary endpoint of ORR was significantly improved from 25% to 33%, p = 0.005, with a 1-month improvement in OS (p = NS) and improved safety. This analysis evaluated efficacy and safety by histology. Methods: Pts with untreated stage IIIB/IV NSCLC were randomized 1:1 (stratified by age, histology, region, stage, and gender) to C AUC 6 day 1 and either nab-P 100 mg/m 2 on days 1, 8, 15 or sb-P 200 mg/m 2 day 1 q 21 days. ORR and PFS were determined by blinded centralized review. Results: In squamous pts, nab-P/C produced a significantly higher ORR (41% vs 24%, p &lt; 0.001), similar PFS (5.6 vs 5.7 mo, HR: 0.865) and &gt;1-month improvement in OS (10.7 vs 9.5 mo, HR: 0.890) vs sb-P/C (Table). nab-P/C was as effective as sb-P/C in nonsquamous pts for ORR (26% vs 25%, p = 0.808), PFS (6.9 vs 6.5 mo, HR: 0.933), and OS (13.1 vs 13.0 mo, HR: 0.950). In both squamous and nonsquamous pts, nab-P/C vs sb-P/C produced lower rates of grade 3/4 neuropathy (3% vs 11% and 3% vs 12%, respectively, p &lt; 0.001 both), neutropenia (43% vs 51%, p = NS, and 50% vs 63%, p = 0.008), and higher but manageable rates of anemia (27% vs 4% and 28% vs 9%, p &lt; 0.001 both) and thrombocytopenia (21% vs 7% and 16% vs 11%, p &lt; 0.001 both). Conclusions: In pts with advanced NSCLC, nab-P/C demonstrated a favorable risk-benefit profile as a first-line therapy regardless of histology. Significantly improved ORR and a positive trend in OS were observed in pts with squamous histology. [Table: see text]
BIOIMPEDANCE ALGORITHMS IN IMPLANTABLE ELECTRONIC CARDIAC DEVICES: RELEVANT DIAGNOSTICS OR WASTE OF TIME?
Authors: Christophe Smeets, Frederik Verbrugge, Julie Vranken, Jo Van der Auwera, Wilfried Mullens, Matthias Dupont, Lars Grieten, Hélène De Cannière, Dorien Lanssens, Thijs Vandenberk, Valerie Storms, Inge Thijs, Pieter Vandervoort
Journal: Journal of the American College of Cardiology (2017)
Relation between long-term blood pharmacokinetics (PK), pharmacogenomics (PG), and severe neurotoxicity in patients undergoing an oxaliplatin (O)-based regimen
Authors: G. Bastian, B. Chibaudel, F. Maindrault-Goebel, C. Garcia-Hejl, F. Bonnetain, C. Rebischung, M. Hebbar, Y. Yataghene, A. de Gramont
Journal: Journal of Clinical Oncology (2009)

e15024 The aim of the study was to investigate the residual blood level of O before each cycle of various oxaliplatin (O)-based protocols, and to explore its predictive value for potential occurrence of a severe neurotoxicity. Methods: Between 11/2005 and 06/2008, 220 Pts were included in a prospective cohort, in 7 French centers. Patients received a minimum of 7 cycles of O. Blood samples were taken before each cycle with a maximum of 12 cycles. In parallel neurotoxicity was assessed by the modified Levi score (grade 0 to 3) and by the Von Frey filament exam. Saliva was collected before the first cycle for genomics analysis. The O concentration was obtained by Atomic Absorption Spectrometry assay. Polymorphism of different targets were investigated (carrier proteins: MRP2, OCT1, OCT2, GSTP1, adducts repair system: ERCC1, ERCC2). Time to first severe neurotoxicity occurrence (TTSN Events: Grade 2 or3) was estimated using Kaplan-Meier. Predictive value of severe neurotoxicity was explored using univariate and multivariate logistic or Cox regressions. Harrel C index was produced. Results: 206 pts with gastro-intestinal cancer had, at the time of analysis, completed follow-up and 171 pts were eligible. 84% received FOLFOX regimen (85mg/m 2 every 2 weeks), the others GEMOX or XELOX (100mg/m 2 every 3 weeks). After cycle 1, 2 and 10, median residual level of O was respectively 0.23 mg/L, 0.40 mg/L and 0.58 mg/L. The maximal concentration was obtained between cycle 5 and cycle 9. Respectively 83 Pts (40%) and 15 pts (7%) had a Gr2 and a Gr3 neurotoxicity. Median time TTSN was 141 days (95% CI: 132 - 161). O concentration before 2nd (HR = 1.39, p = 0.34, C =0.53) or 3rd cycle (HR = 1.00, p = 0.99, C =0.54) were not associated with TTSN. Multivariate logistic and Cox analyses confirmed these results. Conclusions: Despite a trend, which needs to be confirmed, the residual blood level of O is not predictive of a Gr 2 or Gr 3 neurotoxicity in patients with an O based-regimen. With updated data, further statistical analyses will be done to be presented at the next ASCO meeting. They will take into account more precise data as the cycle delay or the dose-intensity of O received by the patients. [Table: see text]
ASSOCIATION OF ANXIOUS AND DEPRESSIVE SYMPTOMATOLOGY WITH CARDIOVASCULAR DISEASE AMONG PATIENTS FROM DIFFERENT STATES IN MEXICO: REDECAR STUDY
Authors: Fernando Petersen-Aranguren, Aldo Suarez, Alejandra Almeida, Alvaro Camacho, Edilberto Peña de Leon, Mario Benavides Gonzalez, Manuel Barrera Bustillos, Ursulo Juarez-Herrera, Jorge Carrillo, Manuel de Los Rios Ibarra, Marco Alcocer Gamba
Journal: Journal of the American College of Cardiology (2017)
Treatment efficacy and tolerance in geriatric oncology
Authors: A. Kumar, H. P. Soares, L. Balducci, B. Djulbegovic
Journal: Journal of Clinical Oncology (2006)

6115 Background: Elderly patients share the majority of the disease burden in cancer. Although 61% of new cancer cases occur among elderly, yet elderly comprise only 25% of the patients enrolled in clinical trials. A systematic review to assess the accurate participation of elderly in randomized clinical trials (RCT) has not been done. Methods: We reviewed all consecutively completed phase III RCTs conducted by 5 National Cancer Institute sponsored cooperative groups. Published papers and study protocols were used to ensure the accuracy of the data extraction. We used a cut-off of age ≥65 to define elderly patients. For trials that did not have an exclusive ≥65 age criteria for enrollment, data were extracted on number of participants ≥65. Outcome between the innovative and the standard treatment was compared. Data were extracted as per the methods recommended by the Cochrane Collaboration. Results: Out of 413 studies, only two trials exclusively enrolled elderly patients (0.5%). 57% (n=235) of the trials did not have any stratification by age. Only 10% of the studies had a stratification age at ≥65 (n=42). Contrary to the general notion that elderly may not respond well to newer chemotherapy combination treatments, overall survival in these two trials exclusively enrolling elderly favored the newer treatments [Hazard ratio (HR) 0.62(95%CI 0.44, 0.87)]. In addition, trials enrolling &gt;40% of elderly had favorable outcomes involving innovative treatments for survival and event-free survival [HR survival 0.85(95%CI 0.77, 0.94), HR event-free survival was 0.76(95%CI 0.64, 0.92)]. Treatment related mortality was similar in the innovative and the standard arms [HR 0.87(95%CI 0.39, 1.96)]. Conclusions: Our data indicate that enrollment of elderly in experimental RCTs is not associated with increased harms to this patient population. Increased participation of elderly may help in finding new treatments that are clinically applicable specifically to this cohort of patients. No significant financial relationships to disclose.
CLINICAL OUTCOMES OF ACUTE ISCHEMIC STROKE PATIENTS STRATIFIED BY CARDIAC TROPONIN-I: A RETROSPECTIVE ANALYSIS
Authors: Dylan Stanger, Siu Him Chan, Samuel Yip, Belinda Rodis, Andrew Starovoytov, Latonia Lam, Sonny Thiara, Christopher Cheung, Stephen Taylor, Ken Kaila, Carolyn Taylor, Krishnan Ramanathan
Journal: Journal of the American College of Cardiology (2017)
CHAGAS HEART DISEASE: A UNITED STATES NATIONAL STUDY
Authors: Srikanth Yandrapalli, Sohaib Tariq, Prakash Harikrishnan, Venkat Lakshmi Kishan Vuddanda, Abdallah Sanaani, Wilbert Aronow, Sachin Sule, Alan Gass, Chhaya Aggarwal, William Frishman, Gregg Fonarow, Ali Ahmed, Gregg Lanier, Howard Cooper, Julio Panza
Journal: Journal of the American College of Cardiology (2017)
The impact of baseline serum testosterone and duration of first-line androgen deprivation therapy on the efficacy of docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors: Robert J. van Soest, Mario A. Eisenberger, Florence Mercier, Ian Tannock, Ronald De Wit
Journal: Journal of Clinical Oncology (2014)

5043 Background: The TAX 327 study was conducted in 1,006 men with mCRPC who were randomized to receive 3-weekly docetaxel (D3), weekly docetaxel, or 3-weekly mitoxantrone (M), each with prednisone. Survival and symptom control were superior following D3 as compared to M. In this post hoc analysis, we aimed to identify factors that could characterize subgroups of patients who obtain the greatest benefit from the use of D3. Methods: Using a Cox model, we investigated the OS benefit obtained from D3 as compared to M in subgroups of baseline testosterone (T) ≥ median and < median, and in subgroups of duration of first-line ADT ≥ median and < median. Duration of first-line ADT was defined as the time from start date of first-line ADT to the start date of subsequent treatment. Results: Baseline characteristics known to predict OS including visceral metastases and Karnofsky performance score were well balanced between patient groups. The analysis demonstrated that D3 was superior to M irrespective of baseline T and the duration of first-line ADT, but demonstrated greater and statistically significant OS benefit in patients with a baseline T ≥ median (14.5 ng/dl) (p=0.035, see table) and in patients with a duration of first-line ADT <median (15 months) (p=0.022). Conclusions: In conclusion, docetaxel is effective in patients with mCRPC irrespective of baseline T and duration of first-line ADT, but demonstrated superior OS benefit in patients with high baseline T and in patients with a short duration of first-line ADT. These results will be further investigated in the dataset of the VENICE study, and require validation in a prospectively designed fashion. Duration of first-line ADT ≥ median Duration of first-line ADT <median Baseline T ≥ median Baseline T < median D3 M D3 M D3 M D3 M Number of patients 182 166 153 166 164 173 171 159 Median OS, months (95% CI) 21.1 (16.7-23.7) 18.6 (14.8-20.8) 18.3 (15.9-20.8) 14.8 (12.3-17.0) 21.1 (16.8-NR) 17.1 (14.8-20.7) 17.4 (15.8-19.8) 15.2 (13.2-18.4) Hazard ratio (95% CI) 0.84 (0.63-1.14) 0.71 (0.54-0.95) 0.72 (0.53-0.98) 0.80 (0.61-1.06) P value 0.261 0.022 0.035 0.124
Detection of local recurrences of limb soft-tissue sarcomas: Is magnetic resonance imaging (MRI) relevant?
Authors: G. Ferron, R. Aziza, M. Delannes, T. Filleron, B. Marquès, D. Labarre, D. Labarre, C. Chevreau
Journal: Journal of Clinical Oncology (2009)

10582 Background: The role of systematic magnetic resonance imaging (MRI) surveillance after resection of soft-tissue sarcomas (STS) of the limb is opened to debate. The aim of our study was to retrospectively evaluate the effectiveness of a MRI surveillance schedule performed in adult patients. Methods: 124 adult patients have been treated from 1996 to 2006 for a non-metastatic limb STS at our centre: 86 patients (70%) had clear resection margins (R0) and 111 patients (90%) received an adjuvant radiotherapy. 663 MRI examinations were performed, with a median of 5 per patient [range: 1 to 5]. The rythm of surveillance schedule was respected in 57% of the examinations. Results: Forty-one patients (33%) prematurely withdrew from the planned radiological surveillance due to metastasis diagnosis (15 cases), 5-year remission duration (5 cases), other reasons (12 cases), and drop out (9 cases). Among the 11 local recurrences (9%) which were observed, MRI was able to detect only 2 asymptomatic local recurrences, 1 with and 1 without synchronous metastasis, both had microscopically involved margins (R1). In contrast, MRI showed 11 false-positive cases. As the predictive positive value of MRI was 42%, clinical surveillance seems to be more effective. The evaluation of the cost of the systematic MRI surveillance is 200,000 euros. Clinical examination failed in 2 cases (2 asymptomatic local recurrences detected by MRI) as did MRI surveillance (2 false negative cases). In our study, cost-effectiveness was better with clinical examination than MRI surveillance. Conclusions: As observed in our study, systematic MRI surveillance is not relevant for the follow-up of all limb soft-tissue sarcomas. A prospective study could be promoted to evaluate the MRI surveillance of patient at high risk of local recurrence. No significant financial relationships to disclose.
Brincidofovir (BCV) Prophylaxis for Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) after Hematopoietic Cell Transplantation (HCT): Clinical Experience at Memorial Sloan-Kettering Cancer Center
Authors: Yeon Joo Lee, Seong Jin Kim, Daniel Burack, Yao-Ting Hayden Huang, Esperanza B Papadopoulos, Ann A. Jakubowski, Genovefa A Papanicolaou
Journal: Blood (2015)